Stories
Sun Pharma Plans $1 Billion Rupee Debt Sale to Refinance Organon Acquisition Loan
F
Firstpost•29-09-2026, 16:19
Sun Pharma Plans $1 Billion Rupee Debt Sale to Refinance Organon Acquisition Loan
- •Sun Pharmaceutical Industries plans to raise approximately Rs 10,000 crore ($1.04 billion) through a rupee-denominated debt sale.
- •The debt sale aims to partly refinance a bridge loan used for the acquisition of US healthcare company Organon & Co.
- •This follows Sun Pharma's earlier syndication of a nearly $12 billion, 18-month bridge loan for the all-cash Organon acquisition.
- •Sun Pharma intends to issue bonds with maturities of two, three, and four years.
- •The move reflects a growing trend among Indian companies to utilize the domestic debt market due to higher US Treasury yields making dollar-denomdenominated borrowing more expensive.
Key Questions Answered
Sun Pharma plans to raise around Rs 10,000 crore ($1.04 billion) through a rupee-denominated debt sale to partly refinance a bridge loan taken to fund its acquisition of US healthcare company Organon & Co.
Sun Pharma plans to issue bonds with maturities of two, three, and four years.
Indian companies are increasingly turning to the domestic debt market as higher US Treasury yields make dollar-denominated borrowing more expensive.
